eric aguiar, M.D.
Advisor
Eric was a partner at Thomas, McNerney & Partners
from
2007 to 2015. Prior to joining Thomas, McNerney, he was a Managing Director of HealthCare
Ventures, a health care focused venture capital firm, from 2001-2007. Eric
is currently a partner at Aisling Capital. Eric
currently sits on the board of
Invitae Corporation (formerly Locus Development, Inc.). His prior board seats
have included Amarin, Oriel Therapeutics, Inc. (acquired by Novartis AG), Virdante Pharmaceuticals, Inc. (acquired by Momenta Pharmaceuticals), CardioKine, Inc. (acquired by Cornerstone Therapeutics), SkinMedica, Inc. (acquired by Allergan), Vaxinate, Inc.,
Metaphore, and 3-D Pharmaceuticals (acquired by Johnson & Johnson). Eric was CEO of Genovo, Inc. (acquired
by Targeted Genetics), a biopharmaceuticals company that specialized in gene
delivery and gene regulation. He was also executive director of TheraTech,
Inc. (acquired by Watson Pharmaceuticals). Eric was a Vice President and
Managing Director of Philadelphia Ventures from 1992 to 1997. He is a member
of the Board of Overseers of the Tufts School of Medicine and a member of
the Council on Foreign Relations. Eric received his Medical Degree with
honors from Harvard Medical School. He graduated with honors from Cornell
University as a College Scholar. Eric was
also a Luce Fellow and is a Chartered Financial Analyst.